Solutions
About Us
Insights
Careers

First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial. Jänne PA, Wang BC, Cho BC, Zhao J, Li J, Hochmair M, Peters S, Besse B, Pavlakis N, Neal JW, Kato T, Wu YL, Nguyen D, Lin J, Lin J, Vranceanu F, Szumski A, Lin HM, Fram RJ, Mok TSK. J Clin Oncol. 2025

Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study. Schmierer K, Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Sellebjerg F, Vermersch P, Jin H, Sponton L, Chudecka A, Gardner L, De Stefano N. Therapeutic Advances in Neurological Disorders. 2025

Further Practical Guidance on Adjusting Time-To-Event Outcomes for Treatment Switching. Watkins C, Kleine E, Miranda M, Bourmaud E, Doehring O. Pharmaceutical Statistics. 2025

Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study. Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Schmierer K, Sellebjerg F, Vermersch P, Jin H, Chudecka A, Kloetgen A, Lin D, Gardner L, De Stefano N. Neurology and Therapy. 2025

Webinar – From Preparation to Innovation in MHRA Inspection Strategy

Webinar – From Toplines to Triumph: Visualizing the Pathways to Regulatory Approval

Webinar – CDISC Data Submission Workshop

Webinar – Expediting Regulatory Submissions Through Automation

eBook – The Good Data Submission Doctor 2025

Webinar – The Evolving Role of Statisticians: Leading Innovation as Clinical Data Scientists in the Age of the Reimagined RCT